600 related articles for article (PubMed ID: 28253536)
21. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C; Dumas PY; Bérard E; Bidet A; Delabesse E; Tavitian S; Leguay T; Huguet F; Borel C; Forcade E; Vergez F; Vial JP; Rieu JB; Lechevalier N; Luquet I; Canali A; Klein E; Sarry A; de Grande AC; Pigneux A; Récher C; Largeaud L; Bertoli S
Blood Cancer J; 2024 May; 14(1):91. PubMed ID: 38821940
[TBL] [Abstract][Full Text] [Related]
22. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
23. A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia.
Pan J; Xue Y; Qiu H; Chen S; Zhang J; Wu Y; Shen J; Wang Y
Cancer Genet Cytogenet; 2010 Dec; 203(2):333-40. PubMed ID: 21156255
[TBL] [Abstract][Full Text] [Related]
24. Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.
Levato L; Gianfelici V; Caglioti F; Russo A; Giugliano E; Mannella A; Molica S
Chemotherapy; 2020; 65(1-2):51-53. PubMed ID: 32570264
[TBL] [Abstract][Full Text] [Related]
25. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
26. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
Lee MH; Song A; Li JY
Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
29. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia.
Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Nair JKKM; Sreedharan H
J Environ Pathol Toxicol Oncol; 2018; 37(2):117-126. PubMed ID: 30055547
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
[TBL] [Abstract][Full Text] [Related]
32. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
33. Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient.
Zámečníkova A; Al Bahar S; Pandita R
Hematology; 2012 Nov; 17(6):321-4. PubMed ID: 22989955
[TBL] [Abstract][Full Text] [Related]
34. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
35. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
[TBL] [Abstract][Full Text] [Related]
36. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
37. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
38. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.
Wang W; Tang G; Cortes JE; Liu H; Ai D; Yin CC; Li S; Khoury JD; Bueso-Ramos C; Medeiros LJ; Hu S
J Hematol Oncol; 2015 Apr; 8():32. PubMed ID: 25888368
[TBL] [Abstract][Full Text] [Related]
39. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Viswanathan K; Roboz G; Chadburn A; Mathew S
Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
[TBL] [Abstract][Full Text] [Related]
40. Saudi Arabian CML patient with a novel four-way translocation at t(9;22;5;2)(q34;q11.2;p13;q44).
Dridi W; Kanfar S; Sleiman PMA; Liu Y; Hakonarson H; Rammah H; Matrouk A
Mol Genet Genomic Med; 2022 Jun; 10(6):e1865. PubMed ID: 35543309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
